Deciphera Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. With business and development operations based in Boston, and dedicated research capabilities in close proximity to the University of Kansas, Deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals has raised $275M across 2 funding rounds on record, the most recent an undisclosed round of $125M announced in Jan 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Deciphera Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Deciphera Pharmaceuticals Funding Rounds
Deciphera Pharmaceuticals raised $150M in a Post-IPO Equity announced in Apr 2022.
9 months later, an undisclosed round of $125M was announced in Jan 2023.
Deciphera Pharmaceuticals Founders and Leadership Team
Contact details for the Deciphera Pharmaceuticals team: 2 of 2 have an email address on file.
Start 14-day free trial →Deciphera Pharmaceuticals Funding Compared to Other Biotechnology Startups
Deciphera Pharmaceuticals' latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Deciphera Pharmaceuticals in Biotechnology and Waltham
Companies Similar to Deciphera Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Deciphera Pharmaceuticals Funding FAQs
What does Deciphera Pharmaceuticals do?
Deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. With business and development operations based in Boston, and dedicated research capabilities in close proximity to the University of Kansas, Deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
How much funding has Deciphera Pharmaceuticals raised?
Deciphera Pharmaceuticals has raised $275M across 2 rounds on record. The most recent is an undisclosed round of $125M announced in Jan 2023.
When did Deciphera Pharmaceuticals last raise funding?
Deciphera Pharmaceuticals' most recent funding round on record is an undisclosed round of $125M, announced in Jan 2023.
Who is the CEO of Deciphera Pharmaceuticals?
Steve Hoerter is listed as CEO at Deciphera Pharmaceuticals.
Where is Deciphera Pharmaceuticals headquartered?
Deciphera Pharmaceuticals is based in Waltham, Massachusetts, United States.
How many employees does Deciphera Pharmaceuticals have?
Deciphera Pharmaceuticals is in the 251-500 employee band.
How does Deciphera Pharmaceuticals' funding compare to other Biotechnology startups?
Deciphera Pharmaceuticals' latest round of $125M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Deciphera Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Deciphera Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.